Elan sales and marketing update

ELN reported net income before one-time charges for its second quarter ended Sept. 30 of IR£8.1million (IR£0.23) compared to net income of IR£4 million (IR£0.13) in the second quarter last year. Revenue was IR£25.4 million vs. IR£21.9 million in last year's quarter. In U.S. dollars, the current period net before one-time charges was $11.5 million (33 cents).

Decreased U.S. shipments of the Prostep nicotine patch were offset by market introductions of the patch in new markets, and sales of the Cardizem SR and CD and Verelan families of cardiovascular drugs, and increased product sales in other worldwide markets. ...